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ABSTRACT 
Background 
Valvular heart disease (VHD) is expected to become more common as the population 
ages.  However, current estimates of its natural history and prevalence are based on 
historical studies with potential sources of bias. We conducted a cross-sectional 
analysis of the clinical and epidemiological characteristics of VHD identified at 
recruitment of a large cohort of older people. 
Methods and Results 
We enrolled 2500 individuals aged ≥65 years from a primary care population and 
screened for undiagnosed VHD using transthoracic echocardiography. Newly 
identified (predominantly mild) VHD was detected in 51% of participants. The most 
common abnormalities were aortic sclerosis (34%), mitral regurgitation (22%), and 
aortic regurgitation (15%). Aortic stenosis was present in 1.3%. The likelihood of 
undiagnosed VHD was 2-fold higher in the two most deprived socioeconomic 
quintiles than in the most affluent quintile, and 3-fold higher in individuals with atrial 
fibrillation. 
Clinically significant (moderate or severe) undiagnosed VHD was identified in 6.4%. 
In addition, 4.9% of the cohort had pre-existing VHD (a total prevalence of 11.3%). 
Projecting these findings using population data, we estimate that the prevalence of 
clinically significant VHD will double before 2050. 
Conclusions 
Previously undetected VHD affects 1 in 2 of the elderly population and is more 
common in lower socioeconomic classes. These unique data demonstrate the 
contemporary clinical and epidemiological characteristics of VHD in a large 
population-based cohort of older people and confirm the scale of the emerging 
  
 
 
epidemic of VHD, with widespread implications for clinicians and healthcare 
resources. 
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INTRODUCTION 
Valvular heart disease (VHD) is an important cause of reduced functional capacity, 
heart failure, arrhythmia, recurrent hospital admission, and early mortality. The 
combination of an ageing population, earlier diagnosis and greater availability of 
surgical and percutaneous interventions heralds a major increase in the healthcare 
resources required for its optimal management.(1,2) 
 
There is therefore a pressing need to better understand the contemporary clinical and 
epidemiological characteristics of VHD, particularly in the elderly population. 
Previous studies have either been hospital based (3) or retrospective in design (4,5) 
and thus subject to significant selection biases. Broader epidemiological studies 
provide limited data and there are no contemporary prospective large-scale 
population-based studies specific to VHD in developed countries. Available 
retrospective data demonstrate an increasing prevalence with age, predominantly as a 
result of degenerative pathophysiology.(3–5) A major increase in the prevalence of 
VHD would therefore seem an inevitable consequence of the anticipated increase in 
the number of older people in the population. Reliable contemporary data 
demonstrating the prevalence of VHD are an essential requirement for researchers and 
clinicians to improve understanding of its underlying pathophysiology, risk factors, 
and natural history; and for policy makers and economists to plan the provision of 
health services for both surgical and percutaneous interventions and long term 
medical care. 
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Accordingly, we established a large prospective study to provide a unique population-
based evaluation of the contemporary clinical and epidemiological characteristics of 
VHD and create well defined and carefully phenotyped cohorts with individual valve 
lesions for future study.  Herein, we present a cross-sectional analysis of the 
population prevalence of undiagnosed and known VHD in the first 2500 participants 
and quantify the community prevalence of milder forms of VHD for the first time. 
METHODS 
The OxVALVE Population Cohort Study (OxVALVE-PCS) is an ongoing 
prospective cohort study conducted in Oxfordshire, United Kingdom. Methodological 
details have been previously reported elsewhere.(6) In brief, subjects aged 65 years 
and older without known VHD who were registered with one of five primary care 
medical centres were invited to participate. Younger subjects were excluded since (i) 
previous retrospective studies have demonstrated that the prevalence of VHD is low 
in those aged less than 65 years,(4) and (ii) uptake of community screening was likely 
to be low in those with work or family commitments.  The participating medical 
centres were representative of the local population demographics and selected for the 
availability of accurate patient databases with comprehensive search facilities. 
Subjects with a previous diagnosis of VHD (identified using relevant National Health 
Service diagnostic Read codes) were not included in the echocardiographic study but 
their diagnostic data were collected to derive total prevalence. Exclusion criteria 
included terminal illness and immobility or general frailty precluding attendance (as 
judged by the general practitioner/family physician). Eligible subjects received an 
initial study invitation letter with a single follow-up reminder to non-responders - 
further contact with potential study participants was not permitted by the local 
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research ethics committee which approved the study. All participants provided written 
informed consent. 
Participant assessment 
An investigating physician or British Society of Echocardiography (BSE) accredited 
sonographer undertook clinical and transthoracic echocardiographic assessment in the 
participant’s local medical centre.  Socioeconomic class (SEC) was determined using 
Index of Multiple Deprivation (IMD) scores based upon home address postcode. Each 
SEC corresponds to 20% of the national population (with SEC1/SEC5 denoting the 
least/most deprived quintiles, respectively).  
Diagnostic criteria 
The primary outcome was a finding of mild or more severe left sided VHD or 
moderate or more severe right sided VHD. Valve anatomy, physiology and severity of 
VHD were defined according to BSE criteria (7) and international guidelines.(8,9) 
Aortic sclerosis (AoScl) was defined according to 2009 European Association of 
Echocardiography/American Society for Echocardiography guidelines (9) - 
thickening and focal calcification of the aortic valve leaflets, with normal or near 
normal cusp mobility and maximum aortic transvalvular velocity ≤2.5 m/s.  Aortic 
stenosis (AS) was defined as aortic valve thickening or calcification with a maximum 
aortic transvalvular velocity >2.5m/s. 
Statistical analysis 
Participants were stratified by age and gender to explore the prevalence of VHD and 
examine demographic and clinical characteristics. Descriptive statistics for the study 
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cohort are presented using means and standard deviations (SD) for continuous 
variables, and counts (percentages) for categorical variables. Student’s t-test and Chi-
squared test or Fisher’s exact test were used to explore associations between VHD 
and quantitative and categorical variables, respectively. Logistic regression models 
were used to assess associations of newly diagnosed VHD.  For multivariate 
regression, all variables with initial univariate regression p-value < 0.10 were 
included and subsequently removed if the Wald test p-value was  >0.05. All results 
are expressed as odds ratios (ORs) with 95% confidence intervals (CIs) and a 2-tailed 
p-value ≤0.05 considered significant (χ2 distribution p-value with 1 degree of 
freedom). Total prevalence of clinically significant (moderate or severe) VHD was 
obtained by combining data on newly diagnosed and pre-existing VHD (assuming 
that moderate or severe VHD would result in a clinical diagnosis). To derive 
population projections for significant VHD, we applied our age-specific prevalence 
data to Office of National Statistics projections (based upon the 2012 United 
Kingdom census) using gender-specific 5-year age-bands, 
RESULTS 
Demography 
Initial screening of primary healthcare records in study centres demonstrated that 
2.9% of potential participants aged 65 years and older were deceased, 3.1% were no 
longer registered with the practice, and 4.9% had a pre-existing diagnosis of VHD. A 
further 13.2% were excluded from the echocardiographic study for other reasons (e.g. 
cognitive decline, terminal non-cardiac disease or severe immobility). Study uptake 
amongst the remaining potential study population in the first practice to complete 
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recruitment was 53%, consistent with previous community-based echocardiographic 
screening studies for cardiovascular disease (Supplemental Figure 1).(10,11) 
In the first 2500 enrolled participants, the mean age (SD) was 73 (6) years and 51.5% 
were female (Table 1), consistent with the demographics of the wider community 
population - UK 2011 Census data indicate that the mean age of the entire 
Oxfordshire population aged 65 years and older is 75.3 years (55.8% female). Almost 
all the study participants were of White ethnic background (99%) and relatively 
affluent, reflecting the demography of England and Wales, where 95% aged ≥65 years 
are of White ethnicity.(12) Similarly, the socio-economic status of the study cohort 
(assessed by mean Index of Multiple Deprivation (IMD) score) was comparable to 
that of Oxfordshire as a whole (OxVALVE cohort 11.68, Oxfordshire 12.26).(13) 
 The vast majority (97.4%) of the study cohort (excluding those with known VHD) 
had minimal or no symptoms with only 2.6% (65/2500) in New York Heart 
Association Class III/IV. 
Prevalence of valvular heart disease 
OVERALL 
Newly detected (predominantly mild) VHD was identified in just over half (50.8%) of 
this large asymptomatic population (Table 2, Figure 1). The most common valve 
lesion was aortic sclerosis (AoScl, 34% of those with newly detected VHD), followed 
by mitral regurgitation (MR; mild 19.8%, moderate/severe 2.3%) and aortic 
regurgitation (AR; mild 13.6%, moderate/severe 1.6%). Aortic stenosis (AS), the 
most prognostically significant manifestation of VHD, was newly diagnosed in 1.3% 
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of participants at a mean age of 77.3 (7.0) years in men and 75.6 (7.2) years in 
women. A bicuspid aortic valve was found in only 8 (0.3%) participants, reflecting 
the age of the study cohort and the fact that clinical manifestations of this condition 
usually present in the fifth or sixth decades. 
CLINICALLY SIGNIFICANT VALVULAR HEART DISEASE 
Clinically significant (moderate or severe) VHD was newly diagnosed in 6.4% of 
participants.  Addition of the further 4.9% of subjects with pre-existing VHD from the 
overall study cohort (assuming that moderate or severe VHD would result in a clinical 
diagnosis) created a derived total population prevalence of moderate or severe VHD 
of 11.3%. 
RIGHT-SIDED VALVULAR HEART DISEASE 
Significant right-sided VHD was less common. In addition to moderate/severe 
tricuspid regurgitation (2.7%), moderate pulmonary regurgitation was found in 7/2500 
participants (0.3%). There were none with tricuspid or pulmonary stenosis.  
MULTIVALVE DISEASE 
Multiple valve lesions were identified in over one third (38.5%) of the study 
population, affecting 47% of those with AoScl, 58% with MR, and 81% with AR 
(Figure 2).  
Association with clinical variables and socioeconomic class 
Participants with newly detected VHD were on average 2.4 years older than those 
without (Table 1) and prevalence increased linearly with age, from 42.4% (379/894) 
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in those aged 65-69 years to 76.3% (103/135) in those aged 85-95 years (Figure 1). 
The proportion with moderate or severe VHD was 3.3% (54/1621) amongst those 
aged 65-74 years, rising to 11.9% (105/879) in those aged ≥75 years. 
We explored associations with clinical characteristics using multiple regression 
(Figure 3A, Supplemental Table 1). After removal of non-significant variables, VHD 
was associated with older age, more deprived SEC, current or previous atrial 
fibrillation (AF), and higher systolic blood pressure. There was no association with 
gender.  Conversely, current smoking, higher heart rate, diastolic blood pressure and 
body mass index were associated with a lower prevalence of VHD. 
Restricting this analysis to subjects with newly diagnosed clinically significant 
(moderate or severe) VHD, there was an association with older age, current or 
previous AF, prior smoking and lower body mass index (Figure 3B). In this smaller 
subset there was no SEC association. 
A history of current or previous AF was present in 109 participants (4.4% of the total 
study population) and independently associated with both a new diagnosis of VHD of 
any severity (OR 1.85, 95% CI 1.18-2.89) and clinically significant (moderate or 
severe) VHD (OR 3.25, 95% CI 1.91-5.52, p<0·001; Figure 3).  Moreover, 
participants with AF had a much higher prevalence of VHD than those in sinus 
rhythm (newly diagnosed VHD 67.9% vs. 32.1%; clinically significant [moderate or 
severe] VHD 21.1% vs. 5.7%), principally related to increased frequency of MR (mild 
33.9% vs. 19.1%; moderate or severe 5.5% vs. 2.2%) and AR (mild 22.0% vs. 13.3%; 
moderate or severe 3.7% vs. 1.6%). By comparison, there was little difference in the 
frequency of aortic sclerosis (38.8% vs. 34.7%) or aortic stenosis (1.9% vs. 1.2%) 
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between these groups. There were no participants with both AF and mitral stenosis in 
this Western European population. 
Population projections 
Combining our data concerning pre-existing and newly diagnosed VHD (and 
assuming no change in age and gender-specific prevalence), we predict a substantial 
rise in the clinical impact (and financial consequences) of clinically significant 
(moderate or severe) VHD within the rapidly expanding elderly population  (Figure 
4). The OxVALVE-PCS data suggest that the number of individuals in the United 
Kingdom (UK) aged 65 years or older with moderate or severe VHD will increase 
from 1.5 million in 2015 to 3.3 million in 2056 (122% increase), with a doubling in 
prevalence by 2046. 
DISCUSSION 
OxVALVE-PCS is the first population-based study of VHD worldwide and 
demonstrates both the prevalence of undiagnosed and known VHD in older people 
and the contemporary clinical and epidemiological characteristics of VHD. Previously 
undetected VHD was detected in just over half of 2500 participants and prevalence 
increased linearly with age.  The total prevalence of clinically significant VHD was 
11.3% when we included subjects with known VHD from the overall population 
cohort. 
 
Previous studies addressing the prevalence of VHD have either been 
retrospective,(4,5) hospital-based,(3) or developed primarily to examine non-valvular 
heart disease.(14) Consistent with these, we demonstrated a significant increase in the 
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prevalence of VHD with age.(3–5,15–17) A previous North American meta-analysis 
demonstrated that the prevalence of moderate or severe left-sided VHD was <1%, 
9.9% and 13.2% in those aged 18-44 years, >65 years and >75 years, respectively.(4) 
Similarly, the prevalence of undiagnosed moderate/severe VHD in those aged ≥75 
years in OxVALVE-PCS was 11.9%.  Moreover, we excluded 4.9% of the overall 
potential community cohort (6.8% of those aged ≥75 years) from our 
echocardiographic study on account of a previous diagnosis of VHD. Although ethical 
constraints restricted access to more detailed information concerning this group, we 
can reasonably assume that most (if not all) of this VHD was clinically significant, 
providing an 11.3% total prevalence of significant VHD in the elderly population 
aged 65 years or older (18.7% of those aged ≥75 years).  These figures are 
significantly higher than estimated in a previous meta-analysis.(4) A new diagnosis of 
moderate or severe VHD remains clinically important and should prompt specialist 
referral for evaluation, treatment and/or long-term surveillance. 
Aortic sclerosis, defined as thickening and focal calcification of the aortic valve 
leaflets without obstruction to flow, is a frequent incidental echocardiographic 
finding. Prevalence increases linearly with age and is estimated at 20-40% in the 
population aged >65 years.(18) Consistent with this, AoScl was detected in one third 
of participants in the present study and was the most common manifestation of VHD. 
Although progression of AoScl to AS is slow and affects only a minority of 
individuals,(19,20) it is now accepted that AoScl is associated with adverse outcome 
over long term follow up and an independent marker of cardiovascular risk.(21,22) 
Whilst on-going research is addressing underlying mechanisms, vigorous vascular 
risk factor management combined with scheduled clinical and echocardiographic 
follow up to monitor potential progression to significant AS is appropriate for 
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individuals with AoScl identified in the context of cardiovascular screening or other 
echocardiographic assessment. 
Aortic stenosis is associated with reduced life expectancy and carries a poor prognosis 
following the onset of symptoms. Aortic valve replacement and transcatheter aortic 
valve implantation are associated with significant reduction in mortality and 
morbidity, even in the very elderly.(23) Early identification of AS remains an 
important priority to avoid excess morbidity and mortality, even in the oldest 
population cohorts, and we were able to detect AS in 1.3% of our study population.	
Although bicuspid aortic valve (BAV) was historically reported in 1-2% of live births, 
more recent studies suggest the prevalence is lower at 0.5-0.8%,(24–27)  consistent 
with the prevalence of 0.3% in OxVALVE-PCS (particularly since those with a 
known BAV would have been excluded from our echocardiographic study). 
Multivariate analysis confirmed a number of expected findings, such as the 
association of VHD with increasing age, current or previous AF, and elevated systolic 
blood pressure. Whilst initially counterintuitive, lower BMI has previously been 
associated with higher prevalence of regurgitant valve lesions, perhaps due the 
increased ease of echocardiographic imaging in thin individuals.(17) Although current 
smoking was associated with less VHD, a concurrent history of coronary heart disease 
(CHD) may have been an important confounding variable.  Both current and ex-
smokers were more likely to have CHD (Supplemental Table 2) and previous 
echocardiography demonstrating associated VHD would have led to exclusion of this 
group from our echocardiographic study. 
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Variation in the prevalence and outcomes of coronary artery disease and stroke 
according to SEC is well described (28) but OxVALVE-PCS demonstrates an 
association between SEC and VHD for the first time.  Whilst this finding should be 
interpreted with caution given the relatively small sample sizes, the rate of VHD in 
the two most deprived groups (SEC 4/5) was approximately double that in the least 
deprived group (SEC 1, Figure 3). This association is not readily explained but could 
reflect a higher burden of unmeasured risk factors, such as exposure to passive 
smoking, or the small but measureable association between SEC and markers of 
ageing.(29) Consistent with local demographics, SEC 1 accounted for 50% of our 
cohort – larger, more diverse studies to analyse inequalities in the prevalence of VHD 
are warranted.  At a practical level, there is a need to devise strategies to enhance 
access to specialist care in less affluent communities to facilitate the earlier diagnosis 
of VHD. 
We identified current or previous AF as the clinical variable most strongly associated 
with newly diagnosed clinically significant (moderate or severe) VHD. These 
participants had a more than three-fold increase in the likelihood of newly diagnosed 
clinically significant VHD.  Although international guidelines indicate the need for 
initial echocardiography in all patients with AF,(30,31) recent recommendations from 
the UK National Institute for Health and Care Excellence (NICE) reaffirm previous 
guidance that routine echocardiography is unnecessary.(32) Our data indicate that AF 
is an important and easily identifiable marker of silent VHD in asymptomatic 
individuals in primary care and that auscultation and routine echocardiography are 
appropriate. Anticoagulation is also of potential importance in this cohort, although 
none of the OxVALVE-PCS participants had a mechanical valve or mitral stenosis 
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with associated AF (the two conditions known to independently increase 
thromboembolic risk in the setting of AF,(33) and for which novel oral anticoagulants 
are unlicensed).  
The unique OxVALVE-PCS cohort will provide a platform for future studies 
examining long-term outcomes and cross-sectional associations of VHD in its earliest 
stages, enabling accurate assessment of the rate of progression in the community, 
exploration of genetic and biomarker associations, and elucidation of factors involved 
in the pathogenesis of this increasingly common condition. 
Limitations 
The present study has inevitable limitations.  Although uptake was over 50% (despite 
ethical constraints permitting mail only contact with potential participants) and 
compatible with similar community-based studies,(10,11) selection bias with over-
representation of motivated healthy individuals is possible.(34) Thus, although it is 
likely that the pragmatic exclusion of the infirm or those with cognitive decline will 
have skewed the data to an indefinable extent, this will, if anything, have led to an 
underestimation of the considerable population burden of VHD. Indeed, previous 
studies amongst nursing home residents have demonstrated very high levels of 
VHD.(35,36) 
The Oxfordshire population is relatively homogeneous and our study population lacks 
ethnic and socioeconomic diversity, which makes it difficult to generalise our findings 
to other communities.  This is, of course, a problem faced by other similar clinical 
studies. For example, a recent US study demonstrated a far lower rate of aortic 
stenosis in African Americans compared with Caucasians but equal rates of severe 
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mitral regurgitation.(37) However, other key epidemiological series (5, 17) have been 
similarly homogeneous despite being population-based, while other important studies 
(16) were limited to single ethnic groups.  Although there have been numerous 
changes in European population dynamics in recent decades, a traditional ethnic 
structure prevails in older cohorts. For example, UK 2011 Census data demonstrate an 
equivalent or higher prevalence of White ethnicity compared with the OxVALVE 
cohort (98.8%) in 71/174 counties in England and Wales and prevalence of 95% or 
more in 120/174 counties.(12) Comparison with other European nations is difficult, 
although Dutch data indicate that 97% of those aged 65 and over in Holland are of 
Western origin,(38) suggesting that the Oxfordshire population is reasonably 
representative of other elderly Western European populations. 
We also recognise that our study cohort (mean IMD score 11.68) and the overall 
Oxfordshire population (mean IMD score 12.26) is relatively affluent in comparison 
with the wider UK South East region (mean IMD score 14.75) or large cities such as 
London (mean IMD score 25.22) where multi-ethnicity and immigrant communities 
are likely to contribute to a greater prevalence of rheumatic valve disease.  
Comparison of our cohort with other UK populations would be of value and such 
collaborative studies are planned within our future research programme. 
Conclusions 
OxVALVE-PCS is the first population-based study worldwide aimed specifically at 
the community detection of VHD.  In a large cohort of 2500 elderly subjects we 
demonstrate a high prevalence of previously unidentified VHD and infer that the 
number of individuals with clinically significant VHD will increase substantially over 
the next five decades. The novel finding of increased VHD in more deprived 
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socioeconomic groups (even in a high-income country such as the UK) places VHD 
amongst the group of diseases that disproportionately affects the poor. Furthermore, 
we demonstrate that clinically significant VHD is three times more common in 
individuals with current or previous AF, which provides an important and easily 
identifiable marker of silent VHD in asymptomatic individuals. These data are 
important for researchers and clinicians in enabling improved understanding of the 
pathophysiology, risk factors, and natural history of VHD; and for healthcare policy-
makers and economists as the size of the elderly population and their health 
expectations increase, and expensive percutaneous treatment options emerge as an 
evidence-based alternative to conventional valve surgery.(39,40) 
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No VHD 
(SD or % of 
those with 
condition) 
VHD 
(SD or % of 
those with 
condition) 
p-value 
Number of participants 1231 (49.2%) 1269 (50.8%)  
Age (years) 71.8 (5.3) 74.2 (6.5) <0.001 
Gender    
Male (%) 612 (50.5%) 600 (49.5%)  
Female (%) 619 (48.1%) 669 (51.9%) 0.239 
Smoking Status    
Non-Smoker 586 (47.6%) 646 (52.4%)  
Ex-Smoker 544 (49.7%) 550 (50.3%)  
Smoker 101 (58.0%) 73 (42.0%) 0.032 
Socioeconomic class    
1 (least deprived) 647 (51.7%) 605 (48.3%)  
2 280 (50.1%) 279 (49.9%)  
3 207 (47.9%) 225 (52.1%)  
4 or 5 (most deprived) 97 (37.9%) 159 (62.1%) <0.001 
NYHA Class    
I/II 1196 (49.1%) 1240 (50.9%)  
III/IV 35 (54.7%) 29 (45.3%) 0.449 
    
History    
Diabetes mellitus 143 (50.7%) 139 (49.3%) 0.645 
Hypertension 508 (45.2%) 615 (54.8%) <0.001 
Hyperlipidaemia 413 (46.3%) 479 (53.7%) 0.032 
Atrial fibrillation 35 (32.1%) 74 (67.9%) <0.001 
Myocardial infarction 51 (38.9%) 80 (61.1%) 0.02 
Coronary angiography 86 (38.4%) 138 (61.6%) <0.001 
Percutaneous coronary intervention 42 (43.3%) 55 (56.7%) 0.276 
Coronary artery bypass grafting 15 (31.9%) 32 (68.1%) 0.024 
Angina 101 (47.4%) 112 (52.6%) 0.628 
Stroke/TIA 60 (38.7%) 95 (61.3%) 0.009 
Rheumatic fever 20 (44.4%) 25 (55.6%) 0.618 
    
Examination    
Heart rate (bpm) 73.9 (11.9) 71.7 (11.7) <0.001 
Systolic blood pressure (mmHg) 138.5 (18.9) 141.5 (19.9) <0.001 
Diastolic blood pressure (mmHg) 79.9 (11.3) 79.1 (11.2) 0.099 
Ankle oedema 163 (53.4%) 142 (46.6%) 0.132 
Body mass index (kg/m2) 27.9 (4.9) 27.3 (5.1) 0.002 
 
Table 1. Demographics of study participants with and without valvular heart 
disease. Results are presented as mean (SD) for continuous variables and numbers 
(%) for categorical variables, with percentage by row for each category. P-value is for 
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t-test (continuous) and Χ2 or Fisher’s Exact Test (categorical) to assess independence 
of VHD from each characteristic/condition. AF = current or previous atrial 
fibrillation. NYHA = New York Heart Association. TIA = transient ischaemic attack. 
VHD = valvular heart disease.  
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None/Trivial Mild 
Significant 
(moderate/severe) 
Any VHD 1231 (49.2%) 1110 (44.4%) 159 (6.4%) 
    
Left-sided VHD None/Trivial Mild 
Significant 
(moderate/severe) 
Mitral regurgitation 1948 (77.9%) 494 (19.8%) 58 (2.3%) 
Mitral stenosis 2491 (99.6%) 7 (0.3%) 2 (0.1%) 
Aortic regurgitation 2118 (84.7%) 341 (13.6%) 41 (1.6%) 
Calcific aortic valve 
disease – aortic sclerosis 
and stenosis 1617 (64.7%) 866 (34.6%)* 17 (0.7%) 
    
     
Right sided VHD None/Trivial/Mild Significant (moderate/severe) 
Tricuspid regurgitation 2433 (97.3%) 67 (2.7%) 
Pulmonary regurgitation 2493 (99.7%) 7 (0.3%) 
 
Table 2. New diagnosis of valvular heart disease. Number of study participants (% 
of total cohort) with newly diagnosed valvular heart disease (there were no cases of 
tricuspid or pulmonary stenosis). VHD = valvular heart disease. * Mild calcific aortic 
valve disease refers to the combined number with aortic sclerosis and mild aortic 
stenosis.  
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Figure 1. Population prevalence of valvular heart disease (VHD) according to 
age. 
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Figure 2. Venn diagram demonstrating the distribution of single and multiple 
left sided valve abnormalities in OxVALVE participants with newly diagnosed 
valvular heart disease. The outer rectangle represents the full cohort (n=2500) and 
the area of each circle is proportionate to the number of participants with different 
manifestations of left sided valvular heart disease. Numbers denote the number of 
participants in each group. 
 
  
  
 
 
26 
 
 
 
Figure 3. Clinical variables associated with a new diagnosis of valvular heart 
disease. Forest plot of odds ratios from multiple regression analysis of clinical 
associations with (A) any valvular heart disease, and (B) significant (moderate/severe) 
valvular heart disease. Only statistically significant variables are shown. Dots 
represent the odds ratio and whiskers represent the 95% confidence interval. CI = 
confidence interval. OR = odds ratio. SEC = socioeconomic class, according to 
national quintile.   
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Figure 4. United Kingdom population projections of diagnosed and undiagnosed 
significant valvular heart disease. Diagnosed estimates are based on the number 
excluded from participation in the present study due to a prior diagnosis of valvular 
heart disease. Undiagnosed estimates are based on the number with newly diagnosed 
significant valvular heart disease in OxVALVE-PCS. 
 
